Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing

  • das Neves J
  • Martins J
  • Sarmento B
  • 31

    Readers

    Mendeley users who have this article in their library.
  • 11

    Citations

    Citations of this article.

Abstract

Microbicides are being developed in order to prevent sexual transmission of HIV. Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is one of the leading drug candidates in the field, currently being tested in various dosage forms, namely vaginal rings, gels, and films. In particular, a ring allowing sustained drug release for 1 month is in an advanced stage of clinical testing. Two parallel phase III clinical trials are underway in sub-Saharan Africa and results are expected to be released in early 2016. This article overviews the development of dapivirine and its multiple products as potential microbicides, with particular emphasis being placed on clinical evaluation. Also, critical aspects regarding regulatory approval, manufacturing, distribution, and access are discussed.

Author-supplied keywords

  • ASPIRE
  • Pre-exposure prophylaxis
  • The Ring Study
  • Vaginal film
  • Vaginal gel
  • Vaginal ring

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • José das Neves

  • João Pedro Martins

  • Bruno Sarmento

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free